SLC22A2 and breast cancer: In an in vivo model of breast cancer, metformin accumulation and subsequent tumor regression was reported to correlate with expression of OCT2, while in BT-20 breast cancer cells, metformin uptake was enhanced and associated with an overexpression of OCT3 [12,13].